文献速递细菌感染、耐药与抗菌药物医院感染防控

EQASIA基质外部质量评估揭示南亚与东南亚检测食源性大肠埃希菌耐药能力不足

Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究依托Fleming Fund与WHO Tricycle项目,于2021至2024年在南亚与东南亚One Health部门开展四轮基质外部质量评估,用模拟肉样考核实验室检测产ESBL、AmpC和碳青霉烯酶大肠埃希菌的能力。结果显示大肠埃希菌鉴定准确率从2021年的75%降至2024年的23.1%,药敏偏差率0.5%至41%,AmpC及ESBL+AmpC表型误分类常见。

要点

  • 大肠埃希菌鉴定准确率由2021年75%降至2024年23.1%,仅一家实验室单轮全对。
  • 药敏试验实验室间偏差率0.5%至41%,AmpC与ESBL+AmpC表型误分类常见。
  • 质控检测随时间仅 modest 改善且仍不完整,提示食源性耐药检测能力持续不足。

核心结论

  • EQASIA基质外部质量评估揭示南亚与东南亚One Health实验室在食源性基质中检测复杂耐药机制存在持续技术缺口。

研究设计与样本

  • 2021至2024年开展四轮基质外部质量评估,每轮含四份冻干模拟肉样,接种表达β-内酰胺耐药表型的大肠埃希菌。
  • 来自10个国家21家实验室参与,采用常规方法进行选择性分离、菌种鉴定、药敏试验和表型分类,结果经在线平台提交并以CLSI标准判读。

主要发现

  • 大肠埃希菌鉴定准确率从2021年的75%下降至2024年的23.1%,仅一家实验室在任一轮次达到完全鉴定准确。
  • 药敏试验表现存在实验室间差异,偏差率范围为0.5%至41%。
  • AmpC及ESBL+AmpC联合耐药表型的误分类常见,质控检测随时间仅 modest 改善且仍不完整。

关键数值与推荐

  • 药敏结果判读采用基于CLSI的 interpretive criteria 和标准化错误分类系统。

临床怎么用

  • 提示区域实验室需加强食源性基质中ESBL、AmpC和碳青霉烯酶大肠埃希菌的鉴定与药敏能力,并完善质控检测。

局限性

  • 仅21家实验室参与四轮评估,结果可能不能完全代表区域整体实验室能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The increasing prevalence of antimicrobial resistance (AMR) in Escherichia coli, notably those producing AmpC, ESBL and carbapenemases among food-producing animals, poses a significant public health threat, especially in low- and middle-income countries. With support from the Fleming Fund and in alignment with the WHO, FAO and WOAH tripartite Tricycle project, the EQASIA Matrix External Quality Assessment (EQA) scheme aimed at evaluating laboratories' proficiency from different One Health (OH) sectors in detecting resistant E. coli from food-like matrices in South and South-East Asia. METHODS: Between 2021 and 2024, four Matrix EQA rounds were implemented across OH sectors. Each round involved four lyophilized simulated meat samples spiked with well-characterized E. coli strains expressing β-lactam resistance phenotypes. Participating laboratories performed selective isolation, species identification, antimicrobial susceptibility testing (AST) and phenotypic classification using routine methods. Results were submitted via a secure online platform and evaluated against expected outcomes, using CLSI-based interpretive criteria and a standardized error categorization system. RESULTS: Twenty-one laboratories from 10 countries participated across the four rounds. Accuracy in E. coli identification declined from 75% in 2021 to 23.1% in 2024. Only one laboratory achieved full identification accuracy in any round. AST performance showed inter-laboratory variation, with deviation rates ranging from 0.5% to 41%. Misclassification of resistance phenotypes, particularly AmpC and combined ESBL + AmpC, was common. Quality control testing improved modestly over time but remained incomplete. CONCLUSIONS: The Matrix EQA revealed critical insights into regional laboratory capacity and highlighted persistent technical gaps in detecting complex resistance mechanisms from food matrices. With the conclusion of the Fleming Fund, maintaining these gains will require sustained national investment, EQA integration into AMR strategies and continued regional coordination to support Tricycle-aligned surveillance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Al-Mir H, Jeyakumar PZ, Kostyanev T, et al. Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia. J Antimicrob Chemother. 2026. PMID: 41934336. doi:10.1093/jac/dkag129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。